Previous 10 | Next 10 |
Onconova Therapeutics, Inc. (ONTX) Q1 2020 Earnings Conference Call May 14, 2020 4:30 PM ET Company Participants Avi Oler - Vice President, Corporate Development & General Counsel Steve Fruchtman - President & Chief Executive Officer Mark Guerin - Chief Financial Officer ...
Onconova Therapeutics (NASDAQ: ONTX ): Q1 GAAP EPS of -$0.03 beats by $0.03 . Revenue of $0.05M (-28.6% Y/Y) misses by $0.04M . Shares -0.5% . Press Release More news on: Onconova Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
NEWTOWN, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today reported financial resul...
NEWTOWN, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that, as discl...
NEWTOWN, Pa., May 07, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the Compa...
NEWTOWN, Pa., April 27, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the nominati...
Onconova Therapeutics (NASDAQ: ONTX ) has filed a prospectus for a $150M mixed shelf offering. More news on: Onconova Therapeutics, Inc., , Healthcare stocks news, Read more ...
Allakos Reports Encouraging Data for Antolimab Allakos (ALLK) announced that it has received positive response from Phase 1 trial of its lead drug candidate antolimab. Phase 1 trial is an open label study designed to evaluate the lead drug candidate in seven patients suffering from moder...
Onconova Therapeutics, Inc. (ONTX) Q4 2019 Earnings Conference Call March 24, 2020 16:30 ET Company Participants Avi Oler - SVP, Corporate Development & General Counsel Steve Fruchtman - President & CEO Mark Guerin - CFO Ric Woodman - CMO Conference Call Participants...
Onconova Therapeutics (NASDAQ: ONTX ) completes enrollment in a Phase 3 clinical trial, INSPIRE , evaluating rigosertib in myelodysplastic syndromes (MDS) patients who failed to respond to chemotherapy. More news on: Onconova Therapeutics, Inc., Healthcare stocks news, Stocks on the mov...
News, Short Squeeze, Breakout and More Instantly...
Onconova Therapeutics Inc. Company Name:
ONTX Stock Symbol:
NASDAQ Market:
Onconova Therapeutics Inc. Website:
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova" or "the Company"), a clinical-stage biop...